These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 477047)

  • 1. Absolute bioavailability of digoxin in chronic renal failure.
    Ohnhaus EE; Vozeh S; Nüesch E
    Clin Nephrol; 1979 Jun; 11(6):302-6. PubMed ID: 477047
    [No Abstract]   [Full Text] [Related]  

  • 2. Decreased volume of distribution of digoxin in a patient with renal failure.
    Szefler SJ; Jusko WJ
    Res Commun Chem Pathol Pharmacol; 1973 Nov; 6(3):1095-8. PubMed ID: 4760884
    [No Abstract]   [Full Text] [Related]  

  • 3. [Elimination kinetics and dosage of digoxin in patients in renal failure (author's transl)].
    Ohnhaus EE; Spring P; Dettli L
    Dtsch Med Wochenschr; 1974 Sep; 99(37):1797-803. PubMed ID: 4457307
    [No Abstract]   [Full Text] [Related]  

  • 4. Tritiated digoxin: studies in renal disease in human subjects.
    Doherty JE; Bissett JK; Kane JJ; de Soyza N; Murphy ML; Flanigan WJ; Dalrymple GV
    Int J Clin Pharmacol Biopharm; 1975 Jul; 12(1-2):89-95. PubMed ID: 1100542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Digoxin tablets--a review of the bioavailability problems.
    Sim SK
    Am J Hosp Pharm; 1976 Jan; 33(1):44-8. PubMed ID: 1266866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic aspects of digoxin in patients with terminal renal failure. IV. Clinical implications of own observations with a recent review of literature.
    van der Vijgh WJ; Oe PL
    Int J Clin Pharmacol Biopharm; 1978 Nov; 16(11):540-6. PubMed ID: 730421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparison of bioavailability and enteral absorption of digoxin, beta-acetyldigoxin and beta-methhyldigoxin. Measurement of cumulative renal excretion after a single application (author's transl)].
    Greeff K; Hafner D; Strobach H; Wirth KE
    Arzneimittelforschung; 1977; 27(12):2358-64. PubMed ID: 580051
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical pharmacokinetics of digoxin in Nigerians.
    Iyun AO; Lukanbi FA
    Afr J Med Med Sci; 1988 Mar; 17(1):9-15. PubMed ID: 2834936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic aspects of digoxin in patients with terminal renal failure. I. Off dialysis.
    van der Vijgh WJ
    Int J Clin Pharmacol Biopharm; 1977 Jun; 15(6):249-54. PubMed ID: 881276
    [No Abstract]   [Full Text] [Related]  

  • 10. Optimal therapeutic regimen of famotidine based on plasma concentrations in patients with chronic renal failure.
    Hachisu T; Yokoyama T; Oda Y; Ando K; Hattori Y; Yoshida T
    Clin Ther; 1988; 10(6):656-63. PubMed ID: 2905936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Digoxin pharmacokinetics and dosage requirements in pediatric patients.
    Bendayan R; McKenzie MW
    Clin Pharm; 1983; 2(3):224-35. PubMed ID: 6349908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Digoxin in the elderly and in renal failure. Contribution of erythrocyte 86-rubidium uptake tests.
    Zannad F; Royer RJ; Issartel G; Robert J
    Eur J Cardiol; 1981; 12(5):285-96. PubMed ID: 6265220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Letter: Kinetics of elimination and dosage of digoxin in patients with kidney failure].
    Risler T
    Dtsch Med Wochenschr; 1974 Oct; 99(42):2130-1. PubMed ID: 4426236
    [No Abstract]   [Full Text] [Related]  

  • 14. [Use of drugs in children with renal failure].
    Prandota J; Sarul H
    Pol Tyg Lek; 1984 Dec 17-31; 39(51-52):1731-4. PubMed ID: 6522325
    [No Abstract]   [Full Text] [Related]  

  • 15. The metabolism of tritiated digoxin in renal insufficiency in dogs and man.
    Marcus FI; Peterson A; Salel A; Scully J; Kapadia GG
    J Pharmacol Exp Ther; 1966 Jun; 152(3):372-82. PubMed ID: 5922308
    [No Abstract]   [Full Text] [Related]  

  • 16. Metabolism and rate of elimination of digoxigenin bisdigitoxoside in dogs before and during chronic azotemia.
    Gierke KD; Graves PE; Perrier D; Marcus FI; Mayersohn M; Goldman S
    J Pharmacol Exp Ther; 1980 Mar; 212(3):448-51. PubMed ID: 7359346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Bioavailability of Dilanacin and Dilanacin new].
    Sorger D; Gruber G
    Z Gesamte Inn Med; 1982 Dec; 37(24):849-53. PubMed ID: 7170822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Organ distribution of H3-labelled digoxin in cases of kidney failure].
    Ueda H; Motoki T; Murao S; Iida M; Ikeda T
    Saishin Igaku; 1969 Jul; 24(7):1581-3. PubMed ID: 5355156
    [No Abstract]   [Full Text] [Related]  

  • 19. Absolute bioavailability of digoxin tablets.
    Beveridge T; Nüesch E; Ohnhaus EE
    Arzneimittelforschung; 1978; 28(4):701-3. PubMed ID: 581950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clearance of digoxin in persons with healthy kidneys and in patients with reduced renal function].
    Risler T; Grabensee B; Hausamen TU; Schröder E; Grosse-Brockhoff F
    Verh Dtsch Ges Kreislaufforsch; 1974; 40():306-8. PubMed ID: 4450674
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.